28 April 2023
SHARE NOW
Cell Therapy
Scaling Up
Viral/Non-Viral Vectors
Katja Betts, CEO at PROGEN, discusses the core issues affecting biotechs working with AAV and how these could be addressed at both the individual team and industry-wide levels.
Katja begins by introducing the challenges facing biotechs within AAV, and explores the possibility for devising standards for the field. Katja continues to explore challenges that occur when scaling up AAV operations, before sharing her top tips for developing AAV.
Finally, Katja discusses her AAV ‘headline highlights’ from the past year or so, and suggests what we might be able to expect from the next 5 years.
This interview has been produced in partnership with PROGEN and was recorded at Advanced Therapies Week 2023.
More like this
Scalable, xeno-free expansion of mesenchymal stem cells in a fixed-bed bioreactor
This case study showcases the successful expansion of mesenchymal stem cells (MSCs) using Rooster Bio’s xeno-free MSC platform in Univercells Technologies’ scale-X fixed-bed bioreactor. The collaboration highlights seamless process transfer, rapid cell attachment, optimized harvesting with high viability (>96%), and robust scalability from R&D to GMP manufacturing. Key innovations include predictive bioprocess monitoring with Scalia Vision and cost-effective solutions for advanced therapy manufacturing.
19 February 2025
Must-See Sessions at Advanced Therapies Week 2025: Ry Leahy, Head of Content, Phacilitate
Cell and gene therapies are set to revolutionize the future of medicine, but one of the major hurdles is the production of good quality cells cost-effectively and at scale
10 January 2025
